Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results

CRANBURY, N.J., .....»»

WARREN, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the thi.....»»

-Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD--Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018--Preclinical Studies for CTX110 Targeting CD19+ Malignancies Ha.....»»

WARREN, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ.....»»

– Successfully Completed IPO and Concurrent Private Placement Raising $77 Million in Gross Proceeds – – Initiated Cohort Expansion of ATTCK-20-2 Phase I T.....»»

NORCROSS, Ga., May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial re.....»»

WARREN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today prov.....»»

New $100+ million construction financing secured in December First of three Long Island Power Authority PPAs signed Connecticut project awards totaling 22.2 megawatts now under PPA Record backlog and project awards of nearly $2 billion DANBURY, Conn......»»

TEL AVIV, Israe.....»»

VICTORIA, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSX.....»»

CollPlant Reports Third Quarter 2018 Financial Results and Provides Business Update.....»»

Conference call today at 8:00 a.m. ET NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-st.....»»

REDWOOD CITY, Calif., N.....»»

Net Element Reports Third Quarter 2018 Financial Results and Provides Business Update.....»»

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology i.....»»

Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Off.....»»

WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmac.....»»

FLORHAM PARK, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cell.....»»

Data presented at ESMO and SITC underscore continued clinical progress across platform and pipeline CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN), a clinical-stage immuno-oncology compa.....»»

Phase 3 trial for eryaspase in second line pancreatic cancer enrolling patients Phase 2 trial in triple-negative breast cancer to enroll patients by year end Cash position of €146.9 million ($170 million) as of September 30, 2018 LYON, France and CAM.....»»